Sumary of Africa: Pfizer and BioNTech Announce Collaboration to Manufacture and Distribute Covid-19 Vaccine Doses Within Africa:
- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union.
- com/news/home/20210721005475/en/ Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s global COVID-19 vaccine supply chain and manufacturing network, which will now span three continents and include more than 20 manufacturing facilities.
- To facilitate Biovac’s involvement in the process, technical transfer, on-site development and equipment installation activities will begin immediately.
- “From day one, our goal has been to provide fair and equitable access of the Pfizer-BioNTech COVID-19 Vaccine to everyone, everywhere,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
- We will continue to explore and pursue opportunities to bring new partners into our supply chain network, including in Latin America, to further accelerate access of COVID-19 vaccines.
- ” “We aim to enable people on all continents to manufacture and distribute our vaccine while ensuring the quality of the manufacturing process and the doses,” said Ugur Sahin, M.
- “We believe that our mRNA technology can be used to develop vaccine candidates addressing other diseases as well.
- This is why we will continue to evaluate sustainable approaches that will support the development and production of mRNA vaccines on the African continent.